<DOC>
	<DOCNO>NCT01228734</DOCNO>
	<brief_summary>The purpose study ass whether progression free survival ( PFS ) time FOLFOX-4 plus cetuximab long FOLFOX-4 alone first-line treatment mCRC Chinese subject RAS wild-type tumor .</brief_summary>
	<brief_title>A Trial Compare Oxaliplatin , Folinic Acid ( FA ) 5-Fluorouracil ( 5FU ) Combination Chemotherapy ( FOLFOX-4 ) With Without Cetuximab 1st Line Treatment Metastatic Colorectal Cancer ( mCRC ) Chinese Rat Sarcoma Viral Oncogene Homolog ( RAS ) Wild-type Patients</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Signed write inform consent ( first second ) Chinese Chinese citizenship Male female subject great equal ( &gt; = ) 18 year age Medically accept effective contraception procreative potential exists ( applicable male female subject least 90 day last dose trial treatment ) Diagnosis histologically confirm adenocarcinoma colon rectum First occurrence metastatic disease ( curatively resectable ) RAS wildtype status tumor tissue At least one measurable lesion computer tomography ( CT ) magnetic resonance imaging ( MRI ) accord RECIST ( irradiated area ) Life expectancy least 12 week Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 trial entry White blood cell count &gt; = 3 × 10x9/L neutrophil &gt; = 1.5 × 10x9/L , platelet count &gt; = 100 × 10x9/L hemoglobin &gt; = 6.21 mmol/L ( 10 g/dL ) Total bilirubin &lt; = 1.5 × upper limit reference range Aspartate transaminase ( AST ) alanine transaminase ( ALT ) &lt; = 2.5 × upper limit reference range &lt; = 5 × upper reference range subject liver metastasis Serum creatinine &lt; = 1.5 × upper limit reference range Recovery relevant toxicity due previous treatment trial entry Previous chemotherapy CRC except adjuvant treatment terminate &gt; 9 month ( oxaliplatinbased chemotherapy ) &gt; 6 month ( nonoxaliplatinbased chemotherapy ) start treatment trial Radiotherapy surgery ( exclude prior diagnostic biopsy ) 30 day trial treatment Previous treatment monoclonal antibody therapy , vascular endothelial growth factor ( VEGF ) pathwaytargeting therapy , epidermal growth factor receptor ( EGFR ) pathwaytargeting therapy , signal transduction inhibitor History organ allograft , autologous stem cell transplantation , allogeneic stem cell transplantation Renal replacement therapy Intake investigational medication within 30 day trial entry Concurrent chronic systemic immune therapy hormone therapy except physiologic replacement Granulocyte colony stimulate factor ( GCSF ) granulocyte macrophage colony stimulate factor ( GMCSF ) within 3 week trial entry ( growth factor may use trial thereafter ) Other nonpermitted concomitant anticancer therapy Known brain metastasis and/or leptomeningeal disease . Subjects neurological symptom undergo CT scan/MRI brain exclude brain metastasis Previous malignancy CRC last 5 year except basal cell cancer skin preinvasive cancer cervix Clinically significant cardiovascular disease , e.g . cardiac failure New York Heart Association class IIIIV , uncontrolled coronary artery disease , cardiomyopathy , uncontrolled arrhythmia , uncontrolled hypertension , history myocardial infarction last 5 year , leave ventricular ejection fraction institutional range normal baseline multiple gated acquisition scan echocardiogram Acute subacute intestinal occlusion history inflammatory bowel disease Active clinically serious infection ( &gt; grade 2 National Cancer InstituteCommon Terminology Criteria Adverse Events ( NCICTCAE ) version 3.0 ) , include active tuberculosis Known declared history human immunodeficiency virus ( HIV ) infection chronic hepatitis B C Peripheral neuropathy &gt; grade 1 Signs symptom suggestive transmissible spongiform encephalopathy , family member suffer ( ed ) Uncontrolled diabetes mellitus , pulmonary fibrosis , acute pulmonary disorder , interstitial pneumonia , liver failure Known hypersensitivity allergic reaction component trial treatment Pregnancy ( absence confirm serum βhuman chorionic gonadotropin test ) breastfeed Ongoing alcohol drug abuse Presence medical psychological condition would permit subject complete trial sign inform consent Participation another clinical trial within past 30 day Other significant disease investigator 's opinion exclude subject trial Legal incapacity limit legal capacity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Metastatic colorectal cancer</keyword>
	<keyword>RAS wild type</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>First line treatment</keyword>
	<keyword>First occurrence metastatic colorectal cancer Chinese subject RAS wildtype</keyword>
	<keyword>status</keyword>
</DOC>